Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes

Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes

Chemically modified mRNA is a new approach for therapeutic protein expression that could be applied to angiogenesis. Here the authors show in a phase 1 clinical trial that a modified mRNA encoding VEGF-A is well tolerated in patients with type 2 diabetes.

Bibliographic Details
Main Authors: Li-Ming Gan, Maria Lagerström-Fermér, Leif G. Carlsson, Cecilia Arfvidsson, Ann-Charlotte Egnell, Anna Rudvik, Magnus Kjaer, Anna Collén, James D. Thompson, John Joyal, Ligia Chialda, Thomas Koernicke, Rainard Fuhr, Kenneth R. Chien, Regina Fritsche-Danielson
Format: Article
Language:English
Published: Nature Publishing Group 2019-02-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-019-08852-4

Internet

https://doi.org/10.1038/s41467-019-08852-4

Similar Items